Notifying a CBD cosmetic in the CPNP: step-by-step guide

Step-by-step guide to notifying a CBD cosmetic on the CPNP portal: CBD cream next to a computer with the product dossier
CPNP notification is the last step in a dossier, not the first: by the time you reach the portal, the work should already be done
Direct answer

How do you notify a CBD cosmetic in the CPNP?

Before placing a CBD cosmetic on the market in the European Union, the responsible person (manufacturer, importer, or whoever assumes that role) must notify it in the CPNP, the European Cosmetic Products Notification Portal, stating its category, formula, labelling and an image of the packaging. Notification is free of charge; it is not an authorisation and no one reviews it. What is reviewed later, during an inspection, is the product information file underpinning it: a safety report signed by a qualified assessor, the origin of the CBD, batch-by-batch THC analysis, good manufacturing practices and evidence supporting what the label claims. In Spain, manufacturers and importers must also file a responsible declaration with the AEMPS. Since April 2026, there has been a European scientific opinion that considers CBD safe up to 0.19%, with residual THC of no more than 0.00025%.

Cosmetics are currently the format with the greatest legal certainty for a product with CBD in Spain (the full overview is in Is it legal to sell CBD in Spain): there is a clear EU Regulation, a notification portal and an authority, the AEMPS, with known criteria. That certainty comes at a price: the procedure requires a robust dossier, and the sector is full of brands that notified a cream in the CPNP in an afternoon and discovered at the first inspection that the portal was not the problem. This guide to notifying a CBD cosmetic in the CPNP walks through the full process, from the origin of the CBD to the label, under the rules in force as of October 2026 and drawing on the experience of Gabriela Sierra, a lawyer specialising in cannabis law who supports brands and laboratories with CBD cosmetics registration. This is general information to understand what must be done and why; reviewing a specific product is done with its formula, supplier and label in front of you.

What the CPNP is—and what it is not

The Cosmetic Products Notification Portal is the European Commission database in which the responsible person registers each cosmetic before placing it on the market, pursuant to Article 13 of Regulation (EC) 1223/2009. It enables Member State authorities and poison centres to know which products exist, who is accountable for them and what they contain. Three clarifications that prevent most misunderstandings:

Myth

“My CBD cream is registered in Europe: I have the CPNP number.”

Reality

The CPNP does not authorise or validate anything. It assigns a reference to what you declare. Compliance responsibility remains entirely with the responsible person, and an inspection will look at the dossier, not the portal screen.

Myth

“CBD is listed in CosIng, so any CBD is fine.”

Reality

CosIng is an ingredient inventory, not a list of authorised substances. What determines whether your CBD is admissible is Annex II of the Regulation (entry 306, narcotics under the 1961 Convention) and the AEMPS criterion on its origin.

Myth

“Once the CPNP is done, I can sell across the EU.”

Reality

The CPNP is EU-wide, but labelling must be in each country’s language, claims are controlled in each market, and in Spain manufacturers and importers must also file a responsible declaration with the AEMPS.

Who is who: responsible person, manufacturer, importer and distributor

Regulation 1223/2009 rests on one figure: the responsible person, a natural or legal person established in the EU who ensures, for each product, compliance with all obligations. If the cosmetic is manufactured in the EU, the manufacturer is the responsible person unless it designates another in writing; if it is imported from a third country, the importer is the responsible person; and a distributor becomes the responsible person if it markets the product under its own name or modifies anything affecting compliance. For a CBD brand that outsources manufacturing to a laboratory, this is the first serious decision: who signs as responsible person and, therefore, who receives the inspection. If the brand does not yet exist as a company, the correct order is the one we describe in setting up a CBD company: first the structure, then the product.

RoleWhat they doKey obligationsWith the AEMPS
Responsible personEnsures product compliance in the EUProduct information file, safety assessment, CPNP notification, labelling, claims, cosmetovigilanceResponds during inspections and to requests; withdraws the product where appropriate
Manufacturer in SpainProduces the cosmetic, for itself or for third partiesGood manufacturing practices (ISO 22716), quality control, qualified personResponsible declaration of activities (RD 85/2018, Art. 18)
ImporterPlaces on the EU market a product manufactured outside the EUIs the responsible person; verifies the dossier and labellingResponsible declaration of importation with the AEMPS
DistributorSells a product already placed on the marketVerifies labelling, batch, durability and language; maintains traceability; does not alter the productNo declaration, unless it becomes the responsible person
Outsourcing brandCommissions manufacturing from a laboratoryIf it markets under its own name, it is usually the responsible person even if it does not manufactureDepends on the allocation of roles under the contract

No dedicated procedureProcedure with the AEMPS

Gabriela Sierra’s view

“The most expensive mistake I see in CBD cosmetics brands is not in the portal: it’s in the contract with the laboratory. Many believe that because they don’t manufacture, they are not responsible for anything. Then the AEMPS request arrives in the brand’s name—the one on the label—and they discover the laboratory has not provided either the safety report or the THC analysis. The responsible person is chosen before production, in writing, and with the dossier in hand.”

CBD as an ingredient: origin, THC and the SCCS 2026 opinion

Before discussing the procedure, the prior question must be resolved: what CBD can a cosmetic contain? The Regulation does not mention cannabidiol by name. Instead, entry 306 of Annex II prohibits narcotics listed in Schedules I and II of the 1961 Single Convention, and that prohibition is the source of the entire debate about the ingredient’s origin.

Synthetic CBD

Admissible

Obtained by chemical synthesis, unrelated to the plant. This is the origin the AEMPS has always accepted without dispute, and the one listed in CosIng with the functions of antioxidant, skin conditioning and skin protecting.

CBD from seeds and leaves

With documentation

Parts of the plant that the 1961 Convention excludes from control. The AEMPS accepts it if the supplier evidences the botanical part of origin and the process, and if residual THC is documented batch by batch.

CBD from flowers or resin

Grey area

Extracts from flowering tops and resin are narcotics under the Convention. The CJEU Kanavape judgment (Case C-663/18, 2020) held that CBD extracted from the whole plant is not, and CosIng added cannabidiol derived from extract; however, the AEMPS has not published a formal change of criterion and, in inspections, it still asks about origin.

Our practical reading: the origin of CBD is not argued on the shelf; it is evidenced in the dossier. We develop this in legal differences between CBD, THC and hemp.

As for THC, it is a controlled substance and cannot be an ingredient; it can only be present as a technically unavoidable impurity, and the only way to evidence that is batch-by-batch analysis. This is where the 2026 development comes in: the European Commission’s Scientific Committee on Consumer Safety (SCCS) adopted, on 26 March, its final opinion on CBD in cosmetics (SCCS/1685/25), published on 24 April. For the first time, there are EU reference figures.

0.19%
Maximum CBD concentration the SCCS considers safe in dermal and oral products (toothpastes, mouthwashes)
0.00025%
Maximum THC impurity (2.5 ppm) in the finished product considered safe by the SCCS
24/04/2026
Publication of the final opinion SCCS/1685/25. Inhalable formats (sprays, aerosols, powders) are excluded

These figures should be read carefully. An SCCS opinion is not law: the Commission may turn it into an entry in Annex III of the Regulation (restricted substances) via the Article 31 procedure, and as of the date of this article it has not done so. However, inspectors and safety assessors already use it as a benchmark, meaning a product with 1% CBD or THC above 2.5 ppm will have to justify in its safety report why it is safe despite exceeding what the scientific committee has considered safe. In Gabriela Sierra’s view, the opinion is good news for the sector because it finally provides an objective reference, and bad news for anyone who has spent years selling “5% CBD” creams with no basis beyond marketing.

Step-by-step guide: from formula to CPNP notification

The steps to notify a CBD cosmetic are set out in the order in which they must be done—which is almost never the order in which they are done. Each step indicates who carries it out, what document it generates and the most common mistake we see.

Define the product and its category

A cosmetic is, by legal definition, a substance intended for the external parts of the body to clean, perfume, change appearance, protect or keep them in good condition. A CBD cream, balm, massage oil or serum fits; an oil “to take” (an unauthorised food, as we explain in Novel Food and CBD oil), a product that promises pain relief, or something you vape, does not.

  • Set out in writing the intended use and area of application.
  • Choose the CPNP category (skin, lips, hair, oral hygiene): it determines the framework formulation and exposure.
  • From the outset, rule out any format that is ingested or inhaled.
WhoThe brand, with its laboratory
DocumentProduct sheet and intended use
Common mistakeDesigning a “cosmetic” oil that the website presents as ingestible or with therapeutic effects

Document the origin of the CBD and require batch-by-batch THC analysis

The origin of the cannabidiol and residual THC are the first two questions in any inspection, and both are answered with supplier documentation, not with the label.

  • CBD technical specification: synthetic, isolate or extract, and from which part of the plant.
  • Certificate of analysis for each batch with quantified THC, and the safety data sheet.
  • Check the INCI name in CosIng (Cannabidiol) and file the entire documentary chain.
WhoThe responsible person, with the supplier
DocumentSpecification, certificates of analysis and safety data sheet
Common mistakeA generic supplier certificate that does not correspond to the batch you used

Commission the safety report (CPSR) from a qualified assessor

Article 10 of the Regulation requires, before marketing, a two-part safety report. It is the document most often missing or incomplete when we review a dossier.

  • Part A: composition, properties, stability, purity and impurities, exposure, toxicological profile and undesirable effects.
  • Part B: assessment signed by a person with a degree in pharmacy, medicine, toxicology or equivalent.
  • For a CBD product, the assessor checks the concentration against the SCCS 0.19% and THC against 2.5 ppm. If the laboratory says it “comes included”, ask to see the signature.
WhoIndependent safety assessor or the laboratory’s assessor
DocumentCosmetic product safety report, Parts A and B
Common mistakeReusing the report for another “similar” formula or a different concentration

Compile the product information file (PIF)

The product information file is the core of compliance; the CPNP is only its reflection. The responsible person keeps it at the EU address shown on the label for ten years from the last batch, and the AEMPS may request it at any time in Spanish or in a language it understands.

  • Product description and safety report.
  • Manufacturing method with a declaration of compliance with good practices.
  • Evidence supporting the claimed effects and data on animal testing.
WhoThe responsible person
DocumentComplete, up-to-date and retrievable PIF
Common mistakeA PIF “at the laboratory” that no one at the brand has seen or knows where it is
Gabriela Sierra, in practice

“The AEMPS doesn’t start by asking about the cream. It starts by asking who the responsible person is, where the dossier is, and where the CBD comes from. Three one-minute questions—and most brands who come to see me for the first time cannot answer all three without calling someone. That minute sets the tone for everything that follows.”

Ensure manufacturing is carried out in accordance with good practices

The Regulation requires manufacturing in accordance with good practices (harmonised standard ISO 22716), and in Spain Royal Decree 85/2018 adds a dedicated procedure with the AEMPS for anyone who manufactures or imports.

  • Manufacturer in Spain: responsible declaration of manufacturing before starting the activity, including premises, in-house or outsourced activities and a qualified person.
  • Importer from outside the EU: responsible declaration of importation.
  • Outsourcing brand: ask the laboratory for a copy of its declaration and its GMP certificate. If it does not have them, your product is not compliant either.
WhoManufacturer or importer
DocumentResponsible declaration with the AEMPS and the manufacturer’s GMP certificate
Common mistakeImporting “some samples” from a non-EU supplier to sell, without an import declaration

Design the labelling and review the claims

Article 19 sets the mandatory content for container and packaging, and Regulation (EU) 655/2013 sets how claims may be made. In CBD cosmetics, the red line is therapeutic claims: they turn the cosmetic into an unauthorised medicinal product and are the most common reason for withdrawal.

  • Mandatory: responsible person and address, nominal content, minimum durability or the period-after-opening symbol, precautions, batch, function and INCI ingredients, in Spanish.
  • Claims: truthful, substantiated and not misleading, with the evidence dossier filed in the PIF.
  • Prohibited: “anti-inflammatory”, “relieves pain”, “for anxiety”, “medicinal cannabis” and any suggestion of ingestion.
WhoThe brand, with legal review
DocumentFinal label artwork and claims substantiation dossier
Common mistakeCorrect label, but a website, social media and marketplace listing full of therapeutic promises

Notify the product in the CPNP

With all of the above ready, the responsible person creates an EU Login account, requests access to the CPNP and registers their organisation. Notification is free of charge, can be saved as a draft, and must be submitted before placing the first unit on the market.

  • Product data: category, name (with translations if sold in other countries), country of origin if imported.
  • Persons data: the responsible person and an emergency contact person.
  • Composition and label: CMR substances, nanomaterials (six months in advance if not in the annexes), formula as a framework formulation, concentrations or ranges, original labelling and an image of the packaging.
WhoThe responsible person (data entry may be delegated)
DocumentProduct CPNP reference, filed in the PIF
Common mistakeNotifying under a framework formulation that does not fit CBD, or with a label different from the actual one

Keep the dossier alive: changes, cosmetovigilance and reviews

The dossier does not close upon notification. Any change to the product or to the rules requires it to be updated, which is why many brands with multiple products opt for ongoing monitoring such as our monthly legal advice for CBD companies.

  • Change of formula, CBD supplier, responsible person or label: update the PIF and, where applicable, the CPNP.
  • Serious undesirable effects: notify the authority in the Member State where they occurred.
  • Regulatory changes (CBD entry in Annex III, AEMPS criterion on origin): review the safety report.
WhoThe responsible person
DocumentChange log, cosmetovigilance notifications
Common mistakeSwitching CBD supplier “because it was cheaper” without new analysis or a review of the safety report
Product information file for a CBD cosmetic: safety report, THC certificate of analysis and manufacturing sheet on a table
The product information file is what the AEMPS requests in an inspection; the CPNP is only its reference

What the product information file contains

Since the product information file is what is actually inspected, it is worth having it clear document by document. This is what the responsible person for a CBD cosmetic must be able to produce:

Product description

Clear identification, qualitative and quantitative formula, category and intended use, including the target population.

Safety report (Parts A and B)

All safety information and the assessment signed by a qualified professional, with explicit reference to CBD concentration and residual THC.

CBD origin and analyses

Ingredient specification, plant part or synthesis, batch-by-batch certificates of analysis with quantified THC, and the safety data sheet.

Manufacturing method and GMP

Process description and declaration of compliance with good practices (ISO 22716), plus the manufacturer’s or importer’s responsible declaration with the AEMPS.

Evidence supporting claims

Tests, studies or bibliography supporting each statement on the label and in marketing in accordance with Regulation 655/2013.

Labelling, CPNP and change log

Final label artwork, CPNP reference, data on animal testing and the history of changes to formula, supplier or responsible person.

Gabriela Sierra

“When a brand shows me its compliance, the first thing I ask for is not the CPNP number; it’s the safety report with the assessor’s signature and the analysis of the latest batch. If it takes them more than a day to find them, I already know how the inspection will go. The dossier is not a one-off procedure: it is a file that must be ready to open the day the doorbell rings.”

What Gabriela Sierra sees in CBD cosmetics dossiers

These are professional practice observations, not statistics: patterns that repeat when the firm reviews dossiers for brands and laboratories, and that explain why most issues with the AEMPS do not start in the portal.

The document most often missing

The safety report with the assessor’s signature. It often exists “at the laboratory”, but the brand listed as responsible person has never had it in hand.

The AEMPS’s first question

The origin of the CBD. Before the concentration, before the label. And the answer that does not work is “the supplier says it’s legal”.

The most repeated reason for withdrawal

A therapeutic claim not on the packaging: it was on the website, in a marketplace listing or in a social media post.

The change that invalidates the most dossiers

Switching CBD supplier on price without new analysis or a review of the safety report. The product remains notified; the dossier no longer describes it.

Claims: what you can say about a CBD cosmetic—and what you cannot

This is the boundary that triggers the most withdrawals. A cosmetic may talk about what it does to the skin; as soon as it talks about what it does to a disease, a symptom or a mood, it ceases to be a cosmetic. Regulation (EU) 655/2013 sets the common criteria (legal compliance, truthfulness, evidence, fairness, impartiality and informed decision-making), and the AEMPS applies them with particular attention to CBD because the ingredient carries a therapeutic image that the product cannot claim.

Claims that turn the product into a medicinal product

  • Anti-inflammatory, analgesic, relieves joint or muscle pain.
  • Treats psoriasis, acne, dermatitis or eczema.
  • Reduces anxiety, helps you sleep, relaxes the nervous system.
  • “Medicinal cannabis”, “therapeutic use”, “clinically proven” without trials to support it.
  • Any suggestion of ingestion or of use other than as a cosmetic.
Gabriela Sierra

“What I find hardest to explain to a CBD cosmetics brand is that its best sales argument is, legally, its greatest risk. The customer buys the cream because they believe it will take away their pain, and the Regulation prohibits you from saying that. The solution is not to hint at it with synonyms: an inspector reads ‘soothes joint discomfort’ exactly the same as ‘analgesic’. The solution is to sell skin, not symptoms, and let the ingredient speak for itself.”

And one warning we repeat in every review of compliance for CBD companies and shops: the claim is not only on the label. The product page on the website, the description on a marketplace, social media posts and what the shop assistant says in-store are all product advertising and are inspected in the same way. We have seen it in what is checked in an inspection of a CBD shop: the label was correct and the dossier was opened because of an Instagram post.

Label of a CBD cosmetic showing the INCI ingredient list, batch, period after opening and the responsible person’s details
Responsible person, batch, durability, precautions, function and INCI ingredients: what the label must say—and none of what it cannot say

Errors we see in CBD cosmetics dossiers

These are patterns that repeat in small brands and in experienced laboratories, and that we see both when supporting those who want to open a CBD shop and brands that have been on the market for years. None is exotic; all are costly.

The seven most common failures

  • Notify first and document later. The CPNP can be done in an afternoon; the PIF cannot. If an inspection arrives in between, there is no dossier.
  • Not knowing who the responsible person is. The brand thinks it’s the laboratory; the laboratory thinks it’s the brand. The AEMPS decides based on the label.
  • CBD without traceability. A generic certificate, with no batch and no quantified THC, or an extract whose botanical origin no one can evidence.
  • Recycled safety report. An assessment prepared for another concentration or another base, or without a qualified assessor’s signature.
  • Marketing concentrations. “5% CBD” without justifying why it is safe when the SCCS has set 0.19% as the benchmark.
  • Therapeutic claims outside the label. Websites, social media and marketplaces promising what the packaging does not.
  • Importation without a declaration. A product manufactured outside the EU that enters “as samples” or in an individual’s name and ends up on the shelf.
Gabriela Sierra

“There’s a phrase I hear a lot: ‘we’ve been selling for three years and nothing has ever happened’. That is not a legal argument; it is a description of luck. Cosmetics inspections are not based on how long you’ve been trading; they are driven by competitor complaints, AEMPS campaigns on an ingredient, and what can be seen online. CBD meets all three conditions.”

Gabriela Sierra’s recommendations

For anyone building their first CBD cosmetics line or reviewing one they already sell, these are the guidelines Gabriela repeats in almost every meeting from the lawyer for CBD businesses practice area, and expands on in the firm’s training resources.

  1. Choose the responsible person before choosing the formula. And put it in the contract with the laboratory: who keeps the PIF, who notifies, who responds.
  2. Require the signed safety report before paying for production. It is the evidence that a qualified person has reviewed your CBD concentration and your THC.
  3. Work below what the SCCS considers safe—or justify why you do not. 0.19% and 2.5 ppm THC are now the benchmark for any assessor.
  4. Analyse each ingredient batch and keep the certificate with the product batch. Batch-by-batch traceability is what turns an unavoidable impurity into a documented impurity.
  5. Write your marketing as if the AEMPS were reading it. If a sentence cannot be substantiated with a cosmetic test, it does not go on the website or the label.
  6. Ask the laboratory for its responsible declaration and its good practices certificate. If it does not have them, it is not your laboratory.

Are you about to launch, or do you already sell, CBD cosmetics?

We review the ingredient’s origin, the dossier, the labelling and the claims, and we manage the CPNP notification and the declaration with the AEMPS so that the product withstands an inspection.

Frequently asked questions about the CPNP and CBD cosmetics

Is it mandatory to notify a CBD cosmetic in the CPNP?

Yes. Article 13 of Regulation (EC) 1223/2009 requires the responsible person to notify each cosmetic in the CPNP before placing it on the market in the European Union, regardless of whether it contains CBD. Notification is free of charge and does not replace the product information file or the safety report.

Does the CPNP authorise my product?

No. The CPNP is a notification portal: it records what the responsible person declares and assigns a reference, but no one reviews or approves the content. Compliance responsibility lies entirely with the responsible person, and what authorities inspect is the product information file.

What CBD can be used in cosmetics in Spain?

Annex II of Regulation 1223/2009 prohibits narcotics under the 1961 Convention, which include cannabis resin and extracts. The AEMPS has traditionally accepted synthetic CBD and CBD obtained from non-controlled parts of the plant, and requires the origin to be documented. After the CJEU Kanavape judgment, CosIng also lists cannabidiol derived from extract, but it is advisable to have the origin evidenced and a batch-by-batch THC analysis.

How much CBD and how much THC can a cosmetic contain?

There is not yet a legal limit in the Regulation. The SCCS final opinion of 2026 considers CBD safe up to 0.19% in dermal and oral products, with THC impurities of no more than 0.00025% (2.5 ppm). The Commission may incorporate these figures into Annex III; in the meantime, they are the benchmark used by assessors and inspectors, and exceeding them requires justification in the safety report.

Who is the responsible person if my brand outsources manufacturing?

If the product is manufactured in the EU, the responsible person is the manufacturer unless it designates in writing another person established in the EU, which is often the brand marketing under its own name. If it is imported from outside the EU, the importer is the responsible person. It should be set out in the contract with the laboratory, because the responsible person keeps the dossier, notifies in the CPNP and receives inspections.

What is the product information file and where must it be kept?

It is the set of documents required by Article 11 of the Regulation: product description, safety report, manufacturing method with compliance with good practices, evidence supporting claims and data on animal testing. It must be kept for ten years from the last batch at the responsible person’s address shown on the label, available to the authority, in a language the authority understands.

Do I need to complete any procedure with the AEMPS in addition to the CPNP?

Yes, if you manufacture or import. Royal Decree 85/2018 requires cosmetics manufacturers and importers in Spain to file a responsible declaration with the AEMPS before starting the activity, including their premises, activities and qualified person. A distributor that only sells products already notified by another responsible person does not have that procedure, but it does have obligations to verify labelling and maintain traceability.

Can I say my CBD cream is anti-inflammatory or relieves pain?

No. These are therapeutic claims that attribute to the product an action proper to a medicinal product, and using them turns the cosmetic into an unauthorised medicinal product, leading to withdrawal and penalties. A cosmetic may claim effects on the skin that it can substantiate (moisturising, soothing the feeling of tightness, conditioning), in accordance with Regulation (EU) 655/2013, and that rule also applies to the website, social media and marketplaces.

What this guide is and what it is not

It is general legal information. It explains how a CBD cosmetic is notified in the CPNP and what file supports it, using Regulation 1223/2009, Royal Decree 85/2018, Regulation 655/2013, and the 2026 SCCS opinion as sources, so that a brand or a laboratory can understand the complete process.

It is not legal advice nor does it create a lawyer-client relationship. The compliance of a specific product depends on its formula, the origin of its CBD, the analytics, its label, and its marketing—data that we cannot know here. The AEMPS criteria on the origin of CBD and the possible incorporation of the SCCS opinion into the Regulation may change, and a product that is correct today may require adjustments tomorrow.

It does not replace the safety assessor or the laboratory. Toxicological evaluation is the work of a qualified professional; our job is to ensure that the file, the paperwork, and the claims are where they should be and say what they should say.

If you have a product in progress or in project, it is reasonable to review it before notifying it. At Lawyer Sierra, we look at the complete file, we tell you clearly what is missing and what is redundant, and if the product is well-assembled, we will tell you that too.

Lawyer specializing in cannabis reviewing the file and labeling of a CBD product with a cosmetic brand before notifying it in the CPNP
A file reviewed before notification saves the most uncomfortable conversation: the one that starts with a request from the AEMPS

Each product is different. Let’s review yours.

If you are launching a CBD cosmetic line, if you already sell it, or if you are a laboratory that manufactures for third parties, at Lawyer Sierra we review the origin of the ingredient, the product information file, the labelling and claims, and we manage the notification in the CPNP and the declaration before the AEMPS. Without promises, with expertise and more than a decade of experience in the sector.

Scroll to Top